Lv41
700 积分 2025-10-16 加入
The optimal choice for maintenance therapy in ovarian cancer with HR-proficient (HRp)/unknown status: A comparison of Bevacizumab and Niraparib
10天前
已完结
Profiling the immune repertoire in a phase II trial of niraparib and dostarlimab in recurrent or persistent uterine serous carcinomas
10天前
已关闭
Patient-reported outcomes from the final analysis of the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: Results from the homologous recombination-deficient (HRd) and -proficient (HRp) populations
10天前
已完结
Risk Factors for Niraparib-induced Severe Anemia in Japanese Patients With Ovarian Cancer: A Multicenter Study
10天前
已完结
Real-world safety profile and clinical management of patients (pts) with epithelial ovarian cancer (EOC) who received first-line maintenance (1LM) niraparib therapy: Final results from the 1NSPIRE chart review study
22天前
已完结
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)
22天前
已完结
Marked and Durable Response to DLL3-Directed T-Cell Engager Tarlatamab in a Patient With Metastatic Pulmonary Large Cell Neuroendocrine Carcinoma: A Case Report
1个月前
已关闭
Tarlatamab-Induced Tumor Lysis Syndrome in Small Cell Carcinoma: Case Series
2个月前
已完结
ENGOT-ov62 - reducing chemotherapy duration in high-grade advanced ovarian cancer: A comparison of 3 vs. 6 cycles of platinum-based chemotherapy followed by niraparib maintenance in HRD-positive patients
2个月前
已关闭
皖公网安备34019202002308
